Mizuho analyst Salim Syed downgraded Unity Biotechnology (UBX) to Neutral from Outperform with a price target of $1, down from $6. The firm cut its probability of success for UBX1325 on the technical trial failure. The molecule has potential, and the and full 36-week data “looks decent,” but a strategic partner is now needed to continue its development, and it will take some time for the story to play out, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UBX:
- Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study
- Unity Biotechnology announces complete 36-week results from Phase 2b ASPIRE
- Unity Biotechnology Reports Q1 2025 Financials and Study Updates
- Unity Biotechnology announces publication in NEJM on Phase 2 BEHOLD study
- Buy Rating for Unity Biotechnology’s UBX1325: Promising Phase 2b ASPIRE Trial Data and Novel Senolytic Mechanism in DME Treatment